Because EGF has a smaller molecular weight (~ 6 kDa) than antibodies, targeting EGFR in TME offers unique advantages: the targeted nanomedicine penetrates more deeply into the tumor, and more rapid in vivo clearance can be facilitated 38. The gene discussed is EGFR; the disease is neoplasm.